NFKB1 and pulmonary fibrosis: In bleomycin-induced models of lung fibrosis, EGCG treatment prevented a decrease in body weight, reduced markers of inflammation including levels of TNFα and IL-1β and activities of NF-κB and MPO, decreased markers of lipid peroxidation and increased levels of antioxidants enhancing Nrf2 activity, reduced lung edema, decreased content of hydroxyproline, a collagen breakdown product, and improved the histological picture of the lung [283,284,285] that was associated with the downregulation of MMP-2 and MMP-9, TGF-β1, and α-SMA [286].